Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Down 35.7% in September

Key Points

• Oramed Pharmaceuticals experienced a significant drop in short interest of 35.7% in September, with total short interest decreasing from 348,100 shares to 224,000 shares.
• The company's shares opened at $2.44, with a twelve month high of $3.09 and a low of $1.82; meanwhile, the stock is down 2.8% recently.
• Despite recent stock performance, research analysts rate Oramed Pharmaceuticals as a Sell, with an average rating reflecting ongoing skepticism about the company’s financial health.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 224,000 shares, a decline of 35.7% from the August 31st total of 348,100 shares. Based on an average trading volume of 80,900 shares, the days-to-cover ratio is presently 2.8 days. Based on an average trading volume of 80,900 shares, the days-to-cover ratio is presently 2.8 days.

Oramed Pharmaceuticals Trading Down 2.8%

Shares of ORMP stock opened at $2.44 on Friday. Oramed Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $3.09. The stock has a market capitalization of $100.04 million, a price-to-earnings ratio of -6.97 and a beta of 1.62. The stock has a fifty day simple moving average of $2.25 and a two-hundred day simple moving average of $2.22.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Research analysts predict that Oramed Pharmaceuticals will post -0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ORMP. BML Capital Management LLC lifted its stake in shares of Oramed Pharmaceuticals by 14.3% during the 1st quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock worth $6,464,000 after purchasing an additional 376,841 shares during the last quarter. Peapod Lane Capital LLC lifted its stake in shares of Oramed Pharmaceuticals by 11.0% during the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock worth $540,000 after purchasing an additional 24,985 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after purchasing an additional 17,510 shares during the last quarter. N.E.W. Advisory Services LLC lifted its stake in shares of Oramed Pharmaceuticals by 52.9% during the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 6,540 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Oramed Pharmaceuticals by 36.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 5,000 shares during the last quarter. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (d)" rating on shares of Oramed Pharmaceuticals in a report on Saturday, September 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Oramed Pharmaceuticals has an average rating of "Sell".

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.